Newswise — November 23, 2021Total hip replacement may affect the development of a type of pelvic stress fracture, sacral insufficiency fracture (SIF), suggests a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

In particular, SIF appears more likely to occur on the side opposite from previous total hip arthroplasty (THA), according to the new research by Dr. Isabel Graul and colleagues of University of Jena, Eisenberg, Germany. The study also provides evidence that loss of bone density leading to SIF begins within the first postoperative year following THA.

Study suggests 'spatially different bone remodeling' across the sacrum following THA

Sacral insufficiency fracture occurs as a result of decreased bone mineral density in the sacrum. These fractures most commonly occur in older women, causing low back pain that worsens with activity. SIF is becoming increasingly common as the population ages and live longer, leading to more patients with osteoporosis.

Although several risk factors for SIF have been identified, the role of THA is unclear. Dr. Graul and colleagues designed a two-part study to assess the influence of THA on the development and localization of SIF. In a review of 171 patients diagnosed with SIF, the researchers identified 50 patients with previous THA in one or both hips. The average age was 79 years, and 40 of the patients were women. On average, SIF developed about eight years after THA.

Among the 31 SIF patients who had undergone THA in just one hip, the SIF was located in the opposite side twice as often as in the operative side (42 percent compared with 19 percent, respectively). The remaining 39 percent of patients developed SIF on both sides of the pelvis.

In the second part of the study, the researchers analyzed 39 patients with initially healthy bone mineral density who underwent THA. Changes in bone density were assessed in computed tomography scans performed at 1 year after THA. The results showed a small but significant reduction of bone mineral density in the sacrum, but only on the side opposite from the THA. There was no significant change in bone mineral density in the sacrum on the same side as the THA.

Over time, THA may lead to "spatially different bone remodeling," as a result of changes in load transmission through the pelvis, Dr. Graul and colleagues write. The authors note that a key question remains unresolved: does THA cause decreased bone loss on the opposite side of the sacrum, or does it prevent bone loss on the same side of the sacrum. The researchers conclude, "additional studies focusing on this remodeling process, and assessing different implant designs and longer-term changes, are needed."

Click to read “Does Total Hip Arthroplasty Influence the Development and Localization of Sacral Insufficiency Fractures?“

DOI: 10.2106/JBJS.21.00218

###

About The Journal of Bone & Joint Surgery

The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on TwitterFacebookLinkedIn, and YouTube.

SEE ORIGINAL STUDY